{
  "id": 28424,
  "title": "Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s",
  "url": "https://urgent.news/2026/07/31/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-31T08:00:52.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/podcast/gain-therapeutics-a-first-in-class-disease-modifying-therapy-for-parkinsons/"
  },
  "original_language": "en",
  "account": "In a recent episode of the Labiotech.eu podcast Beyond Biotech, Gene Mack, President and CEO of Gain Therapeutics, discussed the company's groundbreaking approach to developing disease-modifying therapies for Parkinson's disease. With over 25 years of diverse experience in biochemistry, Wall Street analysis, and biotech leadership, Gene brings a wealth of knowledge to his role at Gain Therapeutics, which he joined in 2024 after taking on the CEO position in early 2025.\n\nGain Therapeutics is a clinical-stage biotech firm utilizing an innovative Magellan platform, which merges 3D structural biology with physics-based modeling. This proprietary technology enables the company to discover and develop next-generation allosteric small molecule therapies. Their lead candidate is currently advancing towards Phase 2 trials as a potential first-in-class treatment for Parkinson's disease, demonstrating promising results from Phase 1b data, including biomarker improvements and functional benefits.\n\nDuring the podcast, Gene Mack detailed Gain Therapeutics' mission to focus on disease modification rather than merely symptom relief, and explained why existing Parkinson's therapies fall short in addressing the underlying causes of the disease. He also provided an overview of the origins and evolution of the Magellan platform, highlighting how AI is transforming drug discovery by enhancing efficiency beyond just increasing the speed of research.\n\nThe podcast also touched upon Gain Therapeutics' partnership strategy and the company's path towards the Phase 2 trials, which are crucial for further validating the efficacy and safety of their lead candidate. Furthermore, Gene Mack offered valuable advice for leaders in the field of neurodegeneration, emphasizing the importance of innovative thinking and strategic leadership in advancing treatment options for these challenging disorders.",
  "summary": "Today we welcome Gene Mack, President and CEO of Gain Therapeutics. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease The post Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}